The burden of cancer research has increased multifold in an increasingly risk-adverse society. In a genuine effort to protect patients from adverse events, regulatory burdens and research rigidity in clinical trials have increased to a point at which such protection is outweighing the benefits, and actually harming patients who are unable to be involved in clinical trials. Published in Cancer, November 2013.
By Hagop Kantarjian, Baker Institute scholar for health policy; David J. Stewart, Department of Medicine, University of Ottawa; and Leonard Zwelling, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
